Dengue virus type 1 (DENV 1) is one of four antigenically distinct serotypes of dengue virus, a mosquito‑borne Flavivirus that causes dengue fever and severe dengue. It is an enveloped, positive‑sense, single‑stranded RNA virus belonging to the Flaviviridae family.
Genome and Virology
Like other dengue viruses, DENV 1 has an approximately 10.7 kilobase positive‑sense RNA genome encoding a single polyprotein that is co‑ and post‑translationally cleaved into three structural proteins (capsid, pre‑membrane/membrane and envelope) and seven nonstructural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5). The virion is about 50 nm in diameter with a smooth surface due to densely packed envelope proteins. DENV 1 enters host cells—principally monocytes, macrophages and dendritic cells—through receptor‑mediated endocytosis involving host receptors such as DC‑SIGN and heparan sulfate. Acidification of endosomes triggers fusion and release of the viral genome into the cytoplasm, where translation and replication take place on rearranged endoplasmic reticulum membranes. NS3 functions as a serine protease and helicase, while NS5 serves as an RNA‑dependent RNA polymerase and methyltransferase. DENV 1 virions assemble within intracellular membranes and are secreted via the secretory pathway. Distinct genotypes of DENV 1 circulate globally, reflecting regional genetic diversity and contributing to differences in epidemiology.
Epidemiology and Clinical Notes
Dengue is the most prevalent arboviral disease affecting humans, with an estimated 100–400 million infections annually. DENV 1 has been associated with major outbreaks in Southeast Asia, the Pacific and the Americas since its identification in the 1940s. Infection confers lifelong immunity to DENV 1 but only transient cross‑protective immunity to the other serotypes. Subsequent infection with a heterologous serotype can lead to enhanced viral replication through antibody‑dependent enhancement, increasing the risk of severe dengue characterized by plasma leakage, haemorrhage and shock. Clinical manifestations of DENV 1 infection range from asymptomatic or mild febrile illness to classic dengue fever and, less frequently, severe dengue. Transmission occurs primarily via Aedes aegypti and Aedes albopictus mosquitoes, which thrive in urban environments. Vector control, community education and the development of tetravalent vaccines are central to prevention efforts; however, vaccine efficacy varies by serotype, age and serostatus. Dengue virus type 1 shares the genomic organization and replication strategy of other flaviviruses but has unique antigenic properties that distinguish it from DENV 2, DENV 3 and DENV 4. Its widespread distribution and role in epidemics underscore the importance of surveillance and integrated vector management. Understanding serotype‑specific immunity and cross‑reactivity is crucial for vaccine development and disease control. Related Terms: Dengue Virus 2, Dengue Virus 3, Dengue Virus 4, Flavivirus, Aedes aegypti